Work

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Year: 2020

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2020-140138

Authors: Alice S. Mims, Melhem Solh, Uma Borate, Naveen Pemmaraju, Gautam Borthakur, Gail J. Roboz, Ben Powell, Paul Severson, Bernice Matusow, Jason Halladay, Ching Hsu, Paul Watkins, Chao Zhang, Jackie M. Walling, Athanasios C. Tsiatis, Amy E. DeZern

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Northside Hospital, Oregon Health & Science University, OHSU Knight Cancer Institute, The University of Texas MD Anderson Cancer Center, Cornell University, Weill Cornell Medical Center, Plexxikon (United States), Daiichi Sankyo (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4256469968

FWCI: 0.069

Cites:

Cited by: 2

Related to: 10